Key facts
- ChromaCode’s last known valuation is $153.0M (Feb 2023).
- It has raised $101.0M across 5 recorded rounds; the latest was Seed Round ($3.8M) in Jan 2025.
- Notable investors include Global Brain, New Enterprise Associates, In-Q-Tel, Okapi Venture Capital, California Institute of Technology Endowment — 14 tracked in total.
- ChromaCode has filed 7 Form Ds with the SEC since 2017, most recently Feb 2025 ($3.8M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for ChromaCode
Funding rounds
5 roundsAbout ChromaCode
Developer of a molecular diagnostics technology designed to connect patients to the treatment through smarter, accessible diagnostics. The company's technology blends signal processing and tailored chemistry to allow for multiplexed, low-cost chemistry that integrates into existing laboratory workflows, enabling laboratories to carry out testing of multiple targets in a single sample on common, existing quantitative polymerase chain reaction instrumentation.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2012
- Employees
- 65
- Website
- chromacode.com/
- Ownership
- Privately Held (backing)
ChromaCode doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChromaCode shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChromaCode in its N-PORT filings yet. We sweep new filings monthly.